

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**JDH 京东健康**

**JD Health International Inc.**

**京东健康股份有限公司**

*(A company incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6618)**

## **INSIDE INFORMATION**

### **UNAUDITED UPDATE ON THE 2022 THIRD QUARTER**

This announcement is issued by JD Health International Inc. (the “**Company**” or “**JD Health**”, and together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

#### **Business Update**

- In August 2022, the Ministry of Industry and Information Technology, the National Health Commission, the National Healthcare Security Administration, and the National Medical Products Administration jointly issued the Notice on Strengthening the Monitoring of Production and Storage of Medicines in Short Supply and Medicines Selected for National Centralized Procurement. Leveraging the long-accumulated practical experience in pharmaceutical and healthcare supply chain, JD Health has been selected as one of the key reserve enterprises for drugs in short supply, striving to maximize its dual value as a sentry to monitor drug shortages and ensure supply of medicines in shortage to the general public.
- In the third quarter, JD Health collaborated with a number of domestic and international leading pharmaceutical and healthcare companies to accelerate the integration of physical products and services, and promote business innovation. Specifically, JD Health reached a strategic cooperation with Omron Healthcare, to carry out in-depth collaboration in various fields including service model innovation and digital marketing, effectively encouraging users to engage in proactive healthcare management. JD Health and Yuwell Medical jointly explored the health management solutions for home monitoring and in-hospital nursing based on C2M product customization. In the future, both parties will continue to create synergies and complementarities through multi-point connections between “medical devices + healthcare services” while bringing professional, convenient and efficient healthcare services to more consumers.

- In August 2022, JD Health held the Digital and Intelligent Healthcare conference and debuted its digital and intelligent healthcare solution system designed to promote the high-quality development of the healthcare service system. In addition, JD Health released a comprehensive solution for different hospital to expedite healthcare service scenario integration, data sharing among healthcare institutions, and value unification across healthcare industry participants.

## Unaudited Financial Information

The Company is pleased to announce the unaudited revenue and operating income/(loss) of the Group for the three months ended September 30, 2022 together with comparative figures for the corresponding period of 2021:

	<b>Three months ended September 30,</b>		<b>Change</b> (%)
	<b>2022</b> <i>RMB'000</i> (Unaudited)	<b>2021</b> <i>RMB'000</i> (Unaudited)	
Revenue	<b>10,519,625</b>	7,401,611	42.1
Operating income/(loss)*	<b>77,225</b>	(556,392)	N/A
Non-IFRS operating income **	<b>654,564</b>	350,847	86.6

\* Operating income/(loss) consists of gross profit deducting fulfillment expenses, selling and marketing expenses, research and development expenses, general and administrative expenses, and impairment losses under expected credit loss model, net of reversal.

\*\* We define “non-IFRS operating income” as operating income/(loss) for the period, excluding share-based payment expenses for the period. We exclude this item because it is non-operating in nature, not indicative of our core operating results and business outlook, and it does not generate any cash outflows.

The above information is based on the board of director of the Company’s preliminary review of the internal data currently available and gathered by the Company only and is not intended to be a comprehensive statement of the Group’s financial result. The said information and data have not been audited or reviewed by the Company’s auditors and may be subject to change and adjustment.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**JD Health International Inc.**  
**Mr. Enlin Jin**  
*Executive Director*

Hong Kong, November 21, 2022

*As of the date of this announcement, the Board comprises Mr. Enlin Jin as the executive Director, Mr. Richard Qiangdong Liu and Mr. Qingqing Yi as non-executive Directors, and Mr. Xingyao Chen, Ms. Ling Li, Dr. Jiyu Zhang and Mr. Ying Wu as independent non-executive Directors.*